PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

Stock Information for PharmaCyte Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PharmaCyte Biotech Inc.

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Announces Final Results of Tender Offer
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.